Ian Mortimer
CEOMale0.0Global Dominance: 0.00%
Ian Mortimer is the CEO of Xenon Pharmaceuticals, a biotech firm focused on developing innovative therapies for neurological conditions. Under his leadership, Xenon has made significant strides in epilepsy drug development, particularly with the drug azetukalner, which is on the verge of potential FDA approval.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Xenon CEO Ian Mortimer says the company has raised US$1.4-billion but would need more to take azetukalner to market.
Xenon awaiting critical epilepsy drug study results that could lead to FDA approvalThe Globe and Mail·
Canada· 2026-03-02
Canada· 2026-03-02
